Short-term selective T-lymphocyte depletion can lead to regression of metastases in patients with melanoma

References

[1] Rosenberg S., Restifo N., Yang J., Morgan R., Dudley M. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008; 8: 299-308.

[2] Muul L., Spiess P., Director E., Rosenberg S. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 1987; 138: 989-95.

[3] Rosenberg S., Yannelli J., Yang J. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 1994; 86:1159-66.

[4] Rosenberg S., Aebersold P., Cornetta K. et al. Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumorinfiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 1990:323: 570-Jones Е., Dahm-Vicker М., Golgher D., Gallimore A. CD25+ regulatory T cells and tumor immunity. Immunol. Lett. 2003; 85:141-3.

[5] Jones E., Dahm-Vicker M., Simon A. et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2002; 2:1.

[6] Turk M., Guevara-Patino J., Rizzuto G. et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 2004;200:771-82.

[7] Onizuka S., Tawara I., Shimizu J. et al. Tumor rejection by in vivo administration of anti-CD25 [interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999; 59: 3128-33.

[8] Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J.lmmunol. 1999; 163: 5211-8.

[9] Gattinoni L., Finkelstein S., Klebanoff C. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005; 202: 907-12.

[10] Dudley M., Wunderlich J., Yang J. et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology 2005; 10:2346-57.

[11] Frankel A., Surendranathan A., Black J. et al. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer 2006, 106: 2158-64.

[12] Therasse P., Eisenhauer E., Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur. J. Cancer. 2006; 42: 1031-9.

[13] Attia P., Maker A., Haworth L., Rogers-Freezer L., Rosenberg S. Inability of a fusion protein of IL-2 and diphtheria toxin [Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 2005; 28: 582-92.

[14] Dannull J., Su Z., Rizzieri D. et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005,115: 3623-33.

RIGHTS & PERMISSIONS

Eco-Vector